Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Transvaginal permanent mesh vs native tissue repair Awareness of prolapse (0.5 to 7 years) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 0.83 [0.73, 0.95] | 17 studies · 2932 participants | Moderate |
Transvaginal biological graft vs native tissue repair Surgery for recurrent prolapse (1 to 2 years) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.15 [0.75, 1.77] | 6 studies · 899 participants | Moderate |
Transvaginal biological graft vs native tissue repair Recurrent prolapse on examination · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 0.96 [0.71, 1.29] | 9 studies · 1278 participants | Low |
Transvaginal biological graft vs native tissue repair Visceral injury · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 0.34 [0.04, 3.26] | 2 studies · 254 participants | Low |
Transvaginal biological graft vs native tissue repair Bladder function · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 12.64 [1.6, 100.06] | 2 studies · 143 participants | Very low |
Transvaginal biological graft vs native tissue repair Painful intercourse ‐ de novo dyspareunia · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.3 [0.46, 3.66] | 2 studies · 125 participants | Moderate |
Transvaginal biological graft vs native tissue repair Quality of life · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | no estimate extracted | 3 studies · 112 participants | Very low |
Transvaginal permanent mesh vs native tissue repair Repeat surgery (0.5 to 7 years) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.56 [1.07, 2.26] | 27 studies · 3916 participants | Low |
Transvaginal permanent mesh vs native tissue repair Recurrent prolapse on examination (any compartment) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 0.42 [0.32, 0.55] | 25 studies · 3680 participants | Very low |
Transvaginal permanent mesh vs native tissue repair Visceral injury · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 3.67 [1.63, 8.28] | 14 studies · 1997 participants | Low |
Transvaginal permanent mesh vs native tissue repair Mesh exposure · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 11.1 [6.81, 18.1] | 26 studies · 2980 participants | Moderate |
Transvaginal permanent mesh vs native tissue repair Bladder function · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.5 [1.19, 1.88] | 17 studies · 2001 participants | Moderate |
Transvaginal permanent mesh vs native tissue repair Painful intercourse ‐ de novo dyspareunia · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.22 [0.83, 1.79] | 16 studies · 1308 participants | Moderate |
Transvaginal permanent mesh vs native tissue repair Quality of life · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | no estimate extracted | 9 studies · 1365 participants | Very low |
Transvaginal biological graft vs native tissue repair Awareness of prolapse (1 to 3 years) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 1.06 [0.73, 1.56] | 8 studies · 1374 participants | Moderate |
Summary of findings table ‐ Metformin vs megestrol Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 4.89 [1.56, 15.32] | 2 studies · 83 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Progression of endometrial hyperplasia to endometrial cancer · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.96 [0.16, 402.02] | 3 studies · 156 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Hysterectomy rate · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.39 [0.15, 372.38] | 2 studies · 72 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Abnormal uterine bleeding ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Adverse effects during treatment · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 3.42 [0.13, 88.4] | 1 study · 46 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Progression of endometrial hyperplasia to endometrial cancer · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 1 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Hysterectomy rate · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.12 [0.01, 1.95] | 1 study · 46 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Abnormal uterine bleeding · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.61 [0.16, 2.27] | 1 study · 49 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ all effects · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 4 [1.15, 13.9] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ nausea · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 5.11 [1.21, 21.68] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ heaviness in lower abdomen · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 1.38 [0.32, 5.85] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ pain in abdomen · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.83 [0.22, 3.18] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Progression of endometrial hyperplasia to endometrial cancer · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 2 studies · 2 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Hysterectomy rate · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.91 [0.05, 15.52] | 2 studies · 85 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Abnormal uterine bleeding · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.91 [0.05, 15.52] | 1 study · 44 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin vs megestrol Adverse effects during treatment ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 3.27 [1.65, 6.51] | 4 studies · 258 participants | Low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Recurrence of endometrial hyperplasia · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
ORT‐based algorithm vs standard starting dose of FSH Live birth or ongoing pregnancy · women undergoing IVF/ICSI Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 1.12 [0.98, 1.29] | 7 studies · 4400 participants | Low |
Anticipated normal responders: higher vs lower dose of FSH IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | no estimate extracted | 1 study · 37 participants | Ungraded |
Anticipated high responders: higher vs lower dose of FSH IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.98 [0.66, 1.46] | 1 study · 521 participants | Low |
ORT‐based algorithm vs standard starting dose of FSH OHSS · women undergoing IVF/ICSI Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.74 [0.42, 1.28] | 5 studies · 2724 participants | Low |
ORT‐based algorithm vs standard starting dose of FSH Clinical pregnancy · women undergoing IVF/ICSI Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 1.04 [0.91, 1.18] | 7 studies · 4400 participants | Low |
Anticipated low responders: higher vs lower dose of FSH 300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 1.2 [0.78, 1.86] | 3 studies · 538 participants | Low |
Anticipated low responders: higher vs lower dose of FSH 400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.77 [0.19, 3.19] | 1 study · 62 participants | Low |
Anticipated low responders: higher vs lower dose of FSH IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 1.33 [0.71, 2.52] | 1 study · 356 participants | Low |
Anticipated normal responders: higher vs lower dose of FSH IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.88 [0.57, 1.36] | 2 studies · 522 participants | Low |
Anticipated normal responders: higher vs lower dose of FSH 225/200 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.98 [0.7, 1.36] | 2 studies · 686 participants | Low |
Anticipated normal responders: higher vs lower dose of FSH IU vs 225 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro… (2024) · Cochrane | OR 0.65 [0.32, 1.32] | 1 study · 135 participants | Low |
Intrauterine injection of autologous platelet‐rich plasma vs no intervention Live birth (or ongoing pregnancy) · women undergoing assisted reproduction Autologous platelet‐rich plasma for assisted reproduction (2024) · Cochrane | OR 1.1 [0.38, 3.14] | 1 study · 94 participants | Very low |